Synonyms: Example 2 [WO2020216781]
Compound class:
Synthetic organic
Comment: Sevabertinib is the INN for an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antineoplastic potential. The chemical structure was obtained from WHO proposed INN list 131 (August 2024). It is one of the compounds claimed in patent WO2020216781A1 [1]. Bayer are one of the patent assignees, and they have an EGFR/ERBB2 inhibitor in early clinical development (BAY 2927088), but as of August 2024, there has been no formal disclosure of this inhibitor's chemical structure.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
3-(3-chloro-2-methoxyanilino)-2-[3-[[(2S)-1,4-dioxan-2-yl]methoxy]pyridin-4-yl]-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one |
International Nonproprietary Names ![]() |
|
INN number | INN |
13219 | sevabertinib |
Synonyms ![]() |
Example 2 [WO2020216781] |
Database Links ![]() |
|
GtoPdb PubChem SID | 500839901 |
PubChem CID | 155234713 |
Search Google for chemical match using the InChIKey | VYQVHWNNPKOJEA-AWEZNQCLSA-N |
Search Google for chemicals with the same backbone | VYQVHWNNPKOJEA |
Search PubMed clinical trials | sevabertinib |
Search PubMed titles | sevabertinib |
Search PubMed titles/abstracts | sevabertinib |
UniChem Compound Search for chemical match using the InChIKey | VYQVHWNNPKOJEA-AWEZNQCLSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | VYQVHWNNPKOJEA-AWEZNQCLSA-N |